Recent Updates
Recently added Catalysts
ZBIO

Zenas BioPharma Appoints Patricia Allen to its Board of Directors

Key Takeaway: Zenas BioPharma Appoints Patricia Allen to its Board of Directors

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+116%
120-day peak, hindsight
Typical move
8.9%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Orelabrutinib
Phase 3 · Multiple Sclerosis (MS) Primary Progressive

Full Press Release Details

Zenas BioPharma Appoints Patricia Allen to its Board of Directors.
Last updated: Mar 6, 2024